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Substrates of muscle metabolism
Muscle is subjected to major modifications of energy require-
ments and as a result regulates the rate of utilization of differ-
ent substrates. There is substantial evidence that muscle
metabolism relies on the activity of membrane proteins which
catalyze the uptake of critical substrates for energy produc-
tion, anabolic processes, or the release of glycolytic metabo-
lites or amino acids. There is an internal «energy store» in the
form of phosphocreatine, which is maintained in equilibrium
with ATP through the catalysis of creatine kinase; therefore,
any fall in ATP concentration leads to the formation of further
ATP from ADP, using the energy of phosphocreatine. Crea-
tine is the substrate for the synthesis of phosphocreatine,
and is taken up into the muscle cell by creatine carriers. A
major substrate under absorptive resting conditions or dur-
ing exercise is glucose, which is taken up via different glu-
cose transporters that are exquisitely regulated by insulin or
exercise. As a result of glucose metabolism, lactate is
formed, especially under conditions in which there is an oxy-
gen deficit, and lactate is released via activity of monocar-
boxylate transporters. In fact, monocarboxylate transporters
are also responsible for the uptake into the muscle cell of ke-
tone bodies (-hydroxybutyrate or acetoacetate), which are
efficient substrates of muscle metabolism. The major lipid
substrates in muscle are fatty acids, which are especially im-
portant in fasting conditions or during aerobic exercise. Al-
though the mechanism of fatty acid uptake is controversial,
there is evidence of the participation of membrane proteins.
L-Carnitine is essential for the synthesis of acyl-carnitine de-
rivatives, which reach the mitochondrial matrix to undergo -
oxidation; in this regard, carnitine is mainly synthesized in liv-
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Abstract
Muscle is a major player in metabolism. It uses large
amounts of glucose in the absorptive state and changes in
muscle insulin-stimulated glucose uptake alter whole-body
glucose disposal. Lipid substrates such as fatty acids or ke-
tone bodies are preferentially used by muscle in certain
physiological conditions. Muscle is also the main reservoir of
amino acids and protein. The activity of many different plas-
ma membrane transporters such as glucose carriers, carni-
tine, creatine or amino acid transporters maintain muscle
metabolism by taking up or releasing substrates or metabo-
lites across the cell surface. The goal of this review is the
molecular characterization of muscle membrane transporter
proteins and the analysis of their regulatory roles.
Resum
El múscul té un paper central en el metabolisme. Així, el mús-
cul utilitza quantitats substancials de glucosa durant l’estat
absortiu, i els canvis en la captació muscular de la glucosa
provoquen alteracions en la utilització global de la glucosa
per l’organisme sencer. El múscul constitueix també el prin-
cipal reservori corporal d’aminoàcids i de proteïnes. A més,
el metabolisme muscular és mantingut mitjantçant l’activitat
de molts diferents transportadors localitzats a la membrana
plasmàtica, com són els transportadors de glucosa, carniti-
na, creatina o aminoàcids; aquests transportadors capten o
alliberen, a través de la membrana plasmàtica de la cèl·lula
muscular, diferents substrats o metabòlits. L’objectiu d’a-
questa revisió consisteix en la caracterització molecular de
les principals proteïnes transportadores presents a la mem-
brana plasmàtica de les cèl·lules musculars, així com l’anàli-
si de les seves propietats reguladores.
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er and kidney and must be taken up by muscle via carnitine
transporters found in the plasma membrane.
Muscle is not only an important site for work performance
and high energy demand, but is also the main reservoir of
amino acids and protein. This is due to the activity of many
different amino acid transporter agencies that take up and
release amino acids. Since a great deal has been learnt re-
cently about these proteins, this review will focus on the
membrane proteins that participate in the metabolism of cre-
atine, glucose, amino acids and lipid substrates such as
fatty acids and ketone bodies in muscle.
Muscle creatine is taken up from the extracellular
milieu
Intracellular phosphocreatine is an essential component of
energy metabolism in muscles and brain since it acts as a
store of high-energy phosphate which can be converted into
ATP by catalysis of creatine kinase. In turn, phosphocreatine
is formed from creatine by creatine kinase. Phosphocreatine
is spontaneously converted into creatinine, which is excreted
by kidney; the daily amount of creatinine excreted in urine is
around 15 mmol (2 g). This loss of creatine has to be replen-
ished either from food or by endogenous synthesis. Creatine
is synthesized from arginine, glycine and methionine in the
liver, pancreas and kidney. Muscles are unable to synthesize
creatine, which must be taken up from the bloodstream.
Creatine is increasingly used by athletes as a dietary sup-
plement to improve physical performance when creatine
phosphate is needed. Indeed, dietary creatine increases
muscle phosphocreatine and creatine concentrations in hu-
mans [1-3]. Several studies indicate that a dietary creatine
supplement enhances performance in high-intensity, short-
term exercise or in intermittent work performance [4, 5], al-
though it does not improve sprint performance in swimmers
or runners [6, 7].
Cardiac and skeletal muscle cells take up creatine by a
mechanism that depends on sodium, shows an apparent
Km for creatine in the micromolar range and is inhibited by
the structural analogues 3-guanidinopropionate or 4-guani-
dinobutyrate [8-10]. Creatine uptake in G8 muscle cells is
stimulated by long-term exposure to insulin, IGF-I, isopro-
terenol or 3,3’,5-triiodothyronine (T3) [9], probably as a con-
sequence of stimulation of Na+-K+-ATPase activity. Howev-
er, there is some controversy as to the effects of insulin on
muscle creatine uptake: whereas some authors reported
stimulation of creatine uptake [11, 12], others have found
that acute treatment with insulin does not alter creatine up-
take by soleus muscle [10]. Creatine uptake by L6 muscle
cells is down-regulated in the presence of extracellular crea-
tine [13] and carbohydrate ingestion increases skeletal mus-
cle creatine accumulation during creatine supplementation
in humans [14]. All these observations indicate that carnitine
uptake is regulated and that changes in creatine uptake in-
fluence the accumulation of creatine by muscle. In conse-
quence, one way to enhance total intracellular creatine in
muscle is to stimulate creatine transport.
Creatine transport is catalyzed in humans by two creatine
transporters, named CRT1 and CRT2, which are encoded
268 Antonio Zorzano, César Fandos and Manuel Palacín
Figure 1. Proposed 12 transmembrane-spanning domain topology model for human creatine transporter (CRT-1).
Putative glycosylation sites are indicated by branches.
by different genes. Creatine transporters belong to the su-
perfamily of Na+- and Cl—dependent neurotransmitter
transporters [15] and, in keeping with this, expression of
CRTs in Xenopus oocytes or in COS-7 cells induces the up-
take of creatine, which is dependent on Na+ and Cl- ions [16,
17]. The stoichiometry of creatine, Na+ and Cl- seems to be
1:2:1 [17]. The creatine transporters have twelve transmem-
brane domains and human CRT1 shows two potential N-gly-
cosylation sites (Figure 1) [18]. Although the specific struc-
ture/function relationship of the creatine transporters has not
been studied, they are very close to GABA and taurine trans-
porters. Cardiac and skeletal muscles together with brain,
kidney and placenta express CRT1 in humans [18]. At pre-
sent, the cDNAs for human, rat, rabbit and Torpedo CRT1
creatine transporters have been identified [16, 18-21]; func-
tional analysis indicates that they encode a creatine trans-
porter which shows a Km for creatine in the micromolar
range, i.e. very similar to the kinetic data obtained in muscle
cells [14]. Human CRT1 gene is located in Xq28, contains 13
exons and spans approximately 8.5 kb of genomic DNA [21,
22]. Unlike the broad expression of CRT1, human CRT2 is
only expressed in testis and is located on chromosome 16
(16p11.2) [23, 24]. There are many unanswered questions
on the biology of muscle creatine transporter such as the
precise mechanism of transport, structure-function relation-
ships, and regulation of subcellular distribution and activity
of the carrier. It has been reported that creatine supplemen-
tation to rats down-regulates the expression of CRT1 in
skeletal muscle [25], which confirms the observation men-
tioned above that extracellular creatine down-regulates cre-
atine uptake [13].
Glucose transport is exquisitely regulated in
muscle
Skeletal muscle accounts for nearly 40% of body mass and
is the main tissue involved in the insulin-induced stimulation
of glucose uptake. Several studies using the euglycemic-hy-
perinsulinemic clamp have shown that at circulating levels of
insulin in the upper physiological range most of the infused
glucose is taken up by skeletal muscle and converted main-
ly into glycogen [26]. Evidence for the role of muscle glu-
cose uptake in overall glucose homeostasis also comes
from studies of transgenic mice over-expressing GLUT1 in
skeletal muscle. Thus, over-expression of GLUT1 in trans-
genic mice increases glucose uptake in muscle, which
leads to low plasma glucose concentrations and an in-
creased glucose disappearance rate after a glucose toler-
ance test [27]. Because of its quantitative role in glucose up-
take, alterations in muscle insulin sensitivity have a profound
impact on whole body glucose disposal. In this regard, non-
insulin-dependent diabetic patients show deficient insulin-
induced glucose transport in skeletal muscle [28, 29]. In-
sulin treatment, exercise or electrical stimulation rapidly
increase the rate at which glucose is taken up. Kinetic analy-
sis of the effects of insulin or contraction on muscle glucose
transport indicates an enhancement in Vmax values [30].
The stimulation of muscle glucose transport is critical since
this process is thought to be a rate-limiting step in the path-
way of glucose utilization in skeletal muscle. Several obser-
vations support this view: a) intracellular free glucose does
not accumulate, regardless of glucose or insulin concentra-
tion, in skeletal muscle from control or streptozotocin-in-
duced diabetic rats [31, 32], b) in normoglycemic condi-
tions, both in the absence of insulin and at sub-maximal
insulin concentrations, glucose clearance is constant in the
perfused rat hindlimb [33], and c) over-expression of GLUT1
in skeletal muscle from transgenic mice leads to a 10-fold in-
crease in muscle glycogen content and a 2-fold increase in
muscle lactate, with no increase in muscle glucose-6-phos-
phate concentrations [34].
Different glucose transporters are expressed in
muscle
Skeletal muscle expresses GLUT1 and GLUT4 glucose
transporters [35]. Besides GLUT4 and GLUT1, there is some
evidence that skeletal muscle of humans, though not that of
rats, expresses GLUT5 [36, 37]. Based on the induction of
fructose transport activity obtained in Xenopus oocytes after
injection of human GLUT5 cRNA [38], it is thought that
GLUT5 accounts for fructose uptake by muscle. It has been
reported recently that skeletal muscle also expresses low
mRNA levels of GLUTX1, a novel glucose transporter with
unknown physiological properties [39].
GLUT4 is the main glucose carrier expressed in skeletal
muscle from adult rats, whereas GLUT1 accounts for only 5-
10% of total glucose carriers [40], which is similar to data re-
ported in isolated rat adipocytes [41]. The structure/function
relationships of these 12 transmembrane domain proteins,
which show both the N and the C-terminal domains oriented
to the cytosol, have recently been reviewed elsewhere [42]
and will not be analyzed here.
Cardiac muscle also expresses both GLUT4 and GLUT1
glucose transporters and, in rat cardiomyocytes, accounts
for about 60% and 40%, respectively, of total glucose carri-
ers [43].
In addition to the differences in their expression levels,
GLUT1 and GLUT4 show a differential localization in the
muscle fibre. Results obtained from sub-cellular division
studies or by immunoelectron microscopy indicate that
GLUT-1 carriers are located mainly in the plasma mem-
brane, whereas GLUT-4 carriers are more abundant in intra-
cellular membranes (see review 35).
The expression of muscle GLUT4 is regulated
The relative abundance of GLUT4 and GLUT1 in skeletal and
cardiac muscles depends on the developmental stage [44].
Thus, during fetal life in the rat, GLUT1 is the predominant
glucose carrier and its expression is markedly repressed
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perinatally [44-46], as a consequence of alterations lying at a
pre-transferral step [44, 45]. In contrast, muscle expression
of GLUT4 is low in the fetal rat and a continuous induction of
GLUT4 mRNA and protein takes place in the perinatal phase
[44-46]. The expression of glucose transporter isoforms dur-
ing perinatal life is consistent with the observation of a high
rate of glucose uptake by fetal rat heart [47].
Thyroid hormones are an important mechanism responsi-
ble for the transition of muscle GLUT1 and GLUT4 expres-
sion during the perinatal phase. This view is based on the
observation that congenital hypothyroidism markedly im-
pairs GLUT4 protein induction when GLUT4 mRNA levels
are low. The effect of the deficit in thyroid hormones on
GLUT4 expression is reversible and a single injection of T3
causes a marked and rapid increase in the levels of GLUT4
mRNA and protein in heart [46]. Similarly, congenital hy-
pothyroidism leads to a substantial enhancement of GLUT1
protein and mRNA levels in heart [46]. Furthermore, T3 injec-
tion in hypothyroid neonates causes a decrease in cardiac
levels of GLUT1 mRNA [46]. Thyroid hormones are also in-
volved in the control of glucose transport in skeletal muscle
in adulthood. Thus, chronic T3 administration stimulates
GLUT4 expression and glucose transport in skeletal muscle
from rats [48, 49].
The role of thyroid hormones in controlling the transition of
glucose transporter carriers from fetal to neonatal levels in
heart is also supported by additional data. Thus, there is
analogous behaviour between circulating concentrations of
thyroid hormone and the induction of cardiac GLUT4 protein
during perinatal development: T4 and T3 levels increase
progressively during postnatal life and reach a plateau 2
weeks after birth [50] and, in parallel, cardiac GLUT4 protein
expression increases after birth, becomes progressively
more abundant, and attains adult levels after day 15 of post-
natal life [44, 46].
The contractile activity dependent on innervation regu-
lates the expression of GLUT1 and GLUT4 in skeletal muscle
in an inverse manner. This is supported by two distinct types
of evidence: a) the induction of GLUT4 and the repression of
GLUT1 take place at the end of fetal life and coincide with
the timing of skeletal muscle innervation [51], and b) the ex-
pression of GLUT1 is enhanced and GLUT4 is repressed in
response to muscle denervation during adult life [51-53].
In addition, chronic low-frequency stimulation of muscle
in vivo or in vitro causes the induction of GLUT4 glucose
transporter expression above basal levels [54-56]. Physical
training increases insulin-mediated whole-body glucose uti-
lization in human subjects, which reflects an adaptation in
muscle elicited by local contraction-dependent mecha-
nisms. Physical training in human beings does not alter mus-
cle insulin receptor function, but does enhance the muscle
content of GLUT-4 [57, 58]. Similarly, chronic exercise en-
hances GLUT-4 expression in rat muscle [59]. In fact, it
seems that a single bout of exercise enhances GLUT4 ex-
pression in muscle [60]. In addition, chronic exercise in-
creases GLUT-4 content in skeletal muscle of obese insulin-
resistant Zucker (fa/fa) rats [61].
In spite of the potential therapeutic importance of GLUT4
gene transcription in muscle, there is relatively little informa-
tion on the specific mechanisms that regulate it. Studies per-
formed in transgenic mice have shown that 2.4 kb of the 5’-
flanking region of the human GLUT4 gene fused to a
chloramphenicol acetyltransferase reporter gene is specifi-
cally expressed in adipose tissue, skeletal muscle and heart
[62], which indicates that the 2.4 kb of the GLUT4 gene con-
tains all the sequence elements needed to confer tissue-
specific expression.
Work using transgenic mice has also shown skeletal mus-
cle-specific DNA elements located within 730 bp of the
GLUT4 5’-flanking DNA [63]. These results are consistent
with other studies in C2C12 muscle cells in culture, which
have shown that GLUT4 muscle-specific expression is con-
ferred by a 103-bp DNA sequence located between -522
and -420 of rat GLUT4 gene [64]. A myocyte enhancer factor
2 (MEF2) binding site in the GLUT4 promoter located be-
tween -466/-457 from the transcription start site has also
been proposed as essential for the specific expression of
GLUT4 in muscle cells [64].
Studies performed in C2C12 muscle cells have shown that
thyroid hormones stimulate the transcription of the rat GLUT4
gene through a 281 bp region in the GLUT-4 promoter locat-
ed between -517 and -237 from the transcription start site
[65]. Recently, Torrance et al. [66] proposed a new, low-affin-
ity binding site for thyroid hormone receptors in GLUT-4 pro-
moter located between bases -457/-426, next to the MEF2
site, although the function of this site has not been demon-
strated. These results are consistent with reports that thyroid
hormones stimulate GLUT4 gene expression in muscle [46].
It has also been reported that 2400 bp of 5’-flanking DNA
is sufficient for regulation of the human GLUT4 gene in trans-
genic mice during fasting and refeeding [62]. Furthermore, a
1154-bp fragment is necessary to direct the insulin-depen-
dent regulation of the human GLUT4 gene in muscle and
adipose tissue from transgenic mice [63].
At present, there are several indications that the regula-
tion of GLUT4 expression in muscle in vivo is due to modifi-
cations not only at a transcriptional level but also post-tran-
scriptionally. Thus, GLUT4 protein diminishes in the
presence of slight or even no changes in GLUT4 mRNA lev-
els in red skeletal muscle from 2-day fasted rats or in white
muscle from streptozotocin-induced diabetes [67]; similarly,
GLUT4 protein decreases in the absence of changes in
mRNA in skeletal muscle from benfluorex-treated rats [68].
GLUT4 protein has also been reported to increase in the
absence of changes in mRNA in rat heart during perinatal
development [44] and in skeletal muscle from the mdx dys-
trophic mouse [69].
However, alterations in tissue levels of GLUT4 mRNA
have been detected in the absence of changes, or in the
presence of inverse changes, in the content of GLUT4 pro-
tein. Thus, in hearts from propylthiouracil- or methylmazole-
induced hypothyroid rats, GLUT4 protein does not change
when GLUT4 mRNA diminishes markedly [46, 70]. In skele-
tal muscle from glucose-induced hyperglycemic rats [71],
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GLUT4 mRNA increases without affecting GLUT4 protein
levels. Similarly, streptozotocin-induced diabetes causes a
large decrease in cardiac GLUT4 mRNA levels, which is,
however, only accompanied by a small decrease in cardiac
GLUT4 protein [67]. The precise mechanisms that regulate
this adaptation - changes in transfer efficiency or rate of
GLUT4 protein degradation - are unknown. However, it has
been reported that treatment of streptozotocin-induced dia-
betic rats with ICI D8731 - an antagonist of the angiotensin
type-1 receptor - for 4 months prevents the reduction of car-
diac GLUT4 protein under conditions in which mRNA levels
stay low [72]. This suggests that angiotensin II influences ei-
ther directly or indirectly the post-transcriptional regulation
of GLUT4 expression in heart.
All these observations suggest that the regulation of mus-
cle GLUT4 expression in transfer or post-transfer steps is
relatively frequent and can involve either the preservation of
GLUT4 carrier levels in the presence of variable changes in
GLUT4 gene expression, or the modification of GLUT4 carri-
ers in the absence of changes in GLUT4 mRNA. These two
inverse patterns can be explained by changes in the transfer
efficiency of GLUT4 transcripts or in the general machinery
of protein synthesis, or by modifications in the rate of GLUT4
protein degradation. In this regard, we have no knowledge
of the specific regulatory mechanisms at transfer and/or
post-transfer. Considerable effort will be required to unravel
the molecular basis for the control of GLUT4 expression in
post-transcriptional steps.
Insulin and muscle contraction translocate GLUT4
to distinct cell surfaces in muscle
As mentioned above, glucose transport in skeletal and car-
diac muscle is thought to be maintained by the catalytic ac-
tivity of two glucose transporter isoforms, i.e. GLUT4 and
GLUT1. In non-stimulated conditions, GLUT1 is found main-
ly in the sarcolemma of the muscle fibre, but not in trans-
verse tubules [40, 73]. In contrast, GLUT4 is mostly associ-
ated with intracellular membranes [35]. Intracellular GLUT4
is found in large elements, including multivesicular endo-
somes located in the trans-Golgi network region, and in
small tubulovesicular structures [74]. Analysis by immuno-
gold labeling of the subcellular distribution in transgenic
mice over-expressing GLUT4 has revealed that most GLUT4
is located in and around the muscle triad [75]. A variety of
experimental approaches have shown that in non-stimulated
conditions GLUT4 is mainly intracellular in cardiac myocytes
[43, 76]. Immunoelectron microscopy of rat heart has shown
that GLUT4 labeling is mostly associated with intracellular
membranous vesicular structures [77]. These tubulo-vesicu-
lar elements are found in different locations: a) perinuclear
elements near the Golgi apparatus, b) near the sarcolemma,
c) near the transverse tubule membranes and d) near the in-
tercalated disks [78].
Immunocytochemical studies, subcellular division and
photolabeling assays (reviewed in 35) indicate that GLUT4
translocates from an intracellular locus to the cell surface of
the muscle fibre in response to insulin or exercise. GLUT4 is
recruited to selective domains of the sarcolemma [73] and
T-tubules of the muscle fiber [74, 79, 80]. There is controver-
sy as to whether insulin unmasks a COOH-terminal GLUT4
epitope in T-tubules in skeletal muscle [74, 75].
There is also evidence that insulin promotes a marked re-
cruitment of GLUT4 carriers to the cell surface in cardiac
myocytes [77]. Indeed, GLUT4 is recruited in response to
the combination of insulin and exercise both to the sar-
colemma and to the T-tubule of cardiac myocytes [77]. In-
sulin also redistributes GLUT1 from an intracellular site to the
cell surface in isolated rat cardiomyocytes or in perfused rat
heart [43, 76, 81]. Nevertheless, the effect of insulin on
GLUT1 is clearly weaker than its effect on GLUT4 [43, 76].
The insulin-dependent recruitment of GLUT1 in cardiomy-
ocytes contrasts with the lack of effect in skeletal muscle,
but is similar to the effect observed in the adipose cell, in
which both GLUT4 and GLUT1 translocate in response to in-
sulin [41].
Exercise or muscle contraction also stimulates glucose
transport and causes GLUT4 translocation to the cell sur-
face in skeletal muscle [82, 83]; the recruitment of GLUT4
triggered by exercise in rat skeletal muscle affects both sar-
colemma and T-tubules [74]. GLUT4 is also translocated to
the cell surface in response to contraction, hypoxia or is-
chemia in cardiac myocytes [84, 85].
In summary, a distinctive feature of muscle cells is that
two distinct cell surfaces, sarcolemma and T-tubules, are in-
volved in GLUT4 recruitment in response to insulin or exer-
cise. As such, there are probably important differences in
GLUT4 traffic between adipose and muscle cells [86].
GLUT4 trafficking pathway in muscle
GLUT4 trafficking involves several steps both in cardiac and
in skeletal muscle. Thus, an intracellular exercise-sensitive
GLUT4 pool has been identified by subcellular division from
rat skeletal muscle; this GLUT4 pool shows no sensitivity to
insulin [87], which indicates that distinct pools may be re-
sponsible for exercise- or insulin-dependent GLUT4 translo-
cation.
Additional evidence has come from the purification of two
intracellular GLUT4 membrane pools from rat skeletal mus-
cle that differ in their response to insulin in vivo: one shows a
marked decrease in GLUT4 levels while the other is unal-
tered [80, 88-91]. These two GLUT4 membrane populations
also differ in their polypeptide composition. Vesicle immuno-
isolation analysis performed in insulin-sensitive or insulin-in-
sensitive intracellular membrane fractions has revealed that
SCAMP proteins (secretory carrier-associated membrane
proteins), transferrin receptors and cellubrevin are only pre-
sent in the insulin-insensitive GLUT4 pool. In contrast,
VAMP2 protein and IRAP (insulin-regulated aminopepti-
dase) are detected in GLUT4 vesicles isolated from both in-
tracellular membrane fractions [90, 91].
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There is also evidence that there are at least two intracel-
lular GLUT4 vesicle populations in rat cardiomyocytes [43].
Thus, GLUT4 vesicles were immuno-isolated by use of vary-
ing amounts of anti-GLUT4 antibody in intracellular mem-
branes from non-stimulated cardiac myocytes [43]. About
40-50% of the GLUT4-vesicles present in intracellular mem-
branes from cardiomyocytes were immuno-isolated by use
of small amounts of anti-GLUT4 antibody: in these condi-
tions, very little GLUT1 or SCAMP protein was detected in
the immunoprecipitates. Larger amounts of antibody
caused maximal immunoadsorption of GLUT4-containing
vesicles: in these conditions most of the GLUT1 and SCAMP
was detected in the immunoprecipitates [43].
Analysis of GLUT4 distribution in skeletal muscle fibers
has also identified distinct intracellular GLUT4 compart-
ments. Thus, in non-stimulated conditions, around 23% of in-
tracellular GLUT4 is associated with large structures located
in the TGN region, and 77% with small tubulovesicular struc-
tures [74]: both compartments are recruited by insulin and
contraction [74]. In turn, the GLUT4 detected in small
tubulovesicular structures can be further subdivided into
transferrin receptor-positive and transferrin receptor-nega-
tive elements [74].
The observations concerning skeletal muscle and car-
diac myocytes are consistent with the presence of at least
two intracellular GLUT4 membrane populations in non-stim-
ulated muscle cells (see Figure 2):
a) an endosomal GLUT4 compartment with a high content
of GLUT1 and SCAMPs (in cardiac myocytes) and high
abundance of SCAMPs, transferrin receptors and cellu-
brevin (in skeletal muscle),
b) storage/exocytic GLUT4 vesicles with low GLUT1 and
SCAMPs content (in cardiomyocytes) and high VAMP2 and
IRAP content (in skeletal muscle).
The pattern of protein composition of these two GLUT4
pools suggests that the storage pool derives from the endo-
somal pool. According to this proposal, GLUT4 would be
sorted from the endosomal membrane population to the
storage/exocytic pool together with VAMP2 or IRAP (at least
in skeletal muscle) and the storage compartment would be
subject to recruitment in response to insulin (Figure 2). In
cardiac myocytes, there is also evidence that insulin recruits
the endosomal compartment to the cell surface [43]. Howev-
er, direct evidence that GLUT4 moves from the cell surface
to the endosomal population, that GLUT4 is sorted from the
endosomal to the storage pool or that exocytic GLUT4-vesi-
cles are recruited directly to the cell surface is lacking.
Putative proteins involved in glucose transporter
trafficking in muscle
As reviewed above, there is evidence that GLUT4 moves
through a series of steps in muscle cells and, therefore, dif-
ferent proteins control the various trafficking processes. Cur-
rent knowledge on this issue is scarce: most of the work has
been done in adipose cells or in heterologous cell systems.
Since non-metabolizable analogues of GTP stimulate
GLUT4 recruitment to the cell surface of permeabilized
adipocytes and cardiac myocytes [92, 93], several authors
have searched for the presence of a GTP-binding protein.
Rab4 (a small GTP-binding protein) was detected in GLUT4
vesicles derived from adipocyte and from skeletal muscle
[94, 95]. Interestingly, rab4 is found in early endosomes in
CHO cells, and is excluded from the recycling compartment
[96, 97]. Its over-expression causes a redistribution of trans-
ferrin receptors from endosomes to the plasma membrane
[98]. The over-expression of rab4 in adipocytes also increas-
es intracellular retention of GLUT4 [99]. Similarly, co-expres-
sion of rab4 and GLUT4 in Xenopus oocytes reduces the
abundance of GLUT4 at the cell surface and diminishes glu-
cose transport [100]. Furthermore, transfer of a synthetic
peptide corresponding to the carboxyl-terminal domain of
rab4 to adipose cells inhibits insulin-induced GLUT4 translo-
cation [101]. Insulin, but not exercise, caused a decrease in
rab4 in intracellular membranes from rat skeletal muscle [95].
All these results support the view that rab4 indeed regulates
GLUT4 trafficking in adipose and muscle cells. All these ob-
servations suggest that rab4 promotes enhanced sorting of
GLUT4 from the endosomal to the storage compartment.
Rab4 is not the only small GTP-binding protein involved in
GLUT4 trafficking in muscle cells. Thus, a small molecular
mass GTP-binding protein, p24, has been detected in
GLUT4 vesicles obtained from rat heart [102]: insulin causes
a marked decrease in the abundance of p24 associated with
intracellular GLUT4-vesicles [102]. This protein and its role
in GLUT4 traffic has not yet been identified.
Vesicle fusion in eukaryotic cells is regulated by vSNARE
and tSNARE proteins. Proteins originally identified as t-
SNAREs involved in synaptic vesicle exocytosis, such as
syntaxin 1A/1B or syntaxin 4, have also been found in cell
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Figure 2. Scheme of proposed GLUT4 traffic pathway in skeletal
muscle and cardiac myocytes.
Results obtained in skeletal muscle and cardiac myocytes are con-
sistent with GLUT4 present in an endosomal compartment (which
selectively contains cellubrevin and SCAMPs in skeletal muscle and
SCAMPs and GLUT1 in cardiac myocytes) and in an exocytic/stor-
age compartment, which contains a more limited number of pro-
teins. This latter compartment is recruited to the cell surface in re-
sponse to insulin. The endosomal compartment comes from
internalization of GLUT4. There is evidence, although not shown in
the scheme, that the endosomal GLUT4 compartment, in isolated
rat cardiac myocytes, undergoes recruitment to the cell surface in
response to insulin (reference 43).
surface membranes from isolated rat adipocytes, cardiomy-
ocytes or skeletal muscle [91, 103]. Furthermore, the v-
SNARE proteins, VAMP2 and cellubrevin, have been detect-
ed in GLUT4 vesicles derived from rat skeletal muscle [91]
and cellubrevin has also been found in GLUT4 vesicles de-
rived from isolated rat cardiomyocytes [91]. These results
are consistent with previous reports indicating that cellu-
brevin and VAMP2 colocalize with GLUT4 in intracellular
membranes obtained from adipocytes [104, 105]. As to the
role of these proteins in GLUT4 traffic, it has been reported
that the cleavage of VAMP2 and cellubrevin by botulinum
neurotoxins B or D inhibits the translocation of GLUT4 in
3T3-L1 adipocytes [106, 107]. In addition, introduction of the
cytoplasmic domains of syntaxin 4, VAMP2 or cellubrevin re-
sults in an inhibition of insulin-stimulated GLUT4 transloca-
tion to the plasma membrane in 3T3-L1 adipocytes [108]. In
summary, the presence of VAMP2 in the exocytic GLUT4
compartment suggests that it plays a role in the docking and
fusion of GLUT4 vesicles to the cell surface in the muscle
fiber. Cellubrevin interacts with syntaxin 1 and SNAP-25
[109] and seems to be involved in exocytosis of transferrin
receptor-containing vesicles in CHO cells [110], but it does
not affect fusion of early endosomes in vitro [111]. As cellu-
brevin is located in the endosomal GLUT4 compartment, it
probably has a role in the fusion events involved in the sort-
ing of GLUT4 from the endosomal to the exocytic pools.
There may also be differences in the specific v- and t-
SNAREs responsible for the traffic of GLUT4 in insulin-sensi-
tive cells. Thus, cardiac myocytes express syntaxin 1A and
1B as well as SNAP-25 and are mainly located at the plasma
membrane [91]. In contrast, adipocytes do not express ei-
ther syntaxin 1 or SNAP-25, although they do express
SNAP23 [112, 113]. In addition, cardiac myocytes do not ex-
press VAMP2, which rules out its role in GLUT4 exocytosis,
unlike what occurs in adipose cells and skeletal muscle, in
which VAMP2 co-localizes with GLUT4 in the storage com-
partment [91, 105]. Whether these differences are attribut-
able to the operation of distinct isoforms or to the acquisition
of v-SNARE proteins during exocytosis is unknown.
Semicarbazide-sensitive amine oxidase has recently
been found to co-localize with GLUT4 in the endosomal
compartment from adipose or muscle cells [114, 115]. Inter-
estingly, substrates of semicarbazide-sensitive amine oxi-
dase in combination with very low concentrations of vana-
date stimulate glucose transport and GLUT4 translocation to
the cell surface in isolated rat adipocytes [115, 116].
Whether these proteins have a regulatory role in GLUT4 traf-
fic remains unanswered.
Another protein that participates in insulin-induced
GLUT4 translocation in cells is protein kinase B, also named
akt, which lies downstream from phosphatidylinositol 3-ki-
nase. In fact, insulin, but not contraction, activates akt in rat
skeletal muscle [117]. Akt-2 has been found in GLUT4 vesi-
cles obtained from isolated rat adipocytes previously treated
with insulin [118]. Furthermore, akt-2 phosphorylates pro-
teins that are components of GLUT4 vesicles in response to
insulin [119]. This strongly supports the concept that akt-2
phosphorylates a component responsible for triggering the
exocytosis of GLUT4 to the cell surface, and might link in-
sulin signaling to activation of GLUT4 exocytosis. No data
are yet available concerning the association of akt-2 and
GLUT4 vesicles in muscle.
Muscles release lactate and take up lactate and
ketone bodies
Metabolism of monocarboxylic acids in muscle
Skeletal muscle produces and removes lactate at the same
time. Lactate is formed during periods of high energy de-
mand or during rapid fluctuations in energy requirements.
The formation of lactate during exercise is a result of an ex-
cess of pyruvate formation and is not necessarily the result
of anaerobic conditions, since lactate can be produced in
oxidative fibres of fully oxygenated muscles. The lactate tak-
en up by the muscle can be used for glycogen synthesis, es-
pecially in fast-twitch fibers [120] or for oxidation in slow-
twitch fibers [121, 122]. Thus, at any given moment, lactate
can be produced in glycolytic fibres and oxidized in more
oxidative fibres. Due to its large mass, skeletal muscle is the
main producer and consumer of lactate in the body. Other
monocarboxylate compounds are ketone bodies and -ke-
toacids derived from amino acids. Ketone bodies are active-
ly consumed by muscle during fasting or during recovery af-
ter exercise, when -hydroxybutyrate or acetoacetate
concentrations in plasma are high. In contrast, it has been
reported that a substantial portion of the branched-chain
amino acids deaminated by muscle are released to the cir-
culation as -ketoacids [123, 124].
Lactate uptake and release are stereospecific, inhibitable
by cinnamate and pH-dependent [125]. Lactate uptake by
soleus muscle shows a Km near 13 mM [126]. Lactate flux
across the membrane regulates intracellular muscle pH.
Thus, measurements of intracellular pH after muscle con-
traction have demonstrated that pH recovery is inhibited by
the lactate transport inhibitor cinnamate [127]. Studies using
sarcolemmal vesicles have revealed that lactate transport is
transactivated by lactate and that high H+ concentration at
the trans-side inhibits the transport [128]. It is also clear that
lactate transport is stimulated by protons at the cis-side,
which has been attributed to fast H+ binding to the carrier
[125]. The transport kinetic parameters and the substrate
selectivity have led to the concept of lactate-proton co-trans-
port in skeletal muscle [129] in which the transport is stere-
ospecific and electroneutral, probably 1:1, and H+ binds first
to the carrier.
Obviously, lactate and H+ efflux from muscle is important
during exercise since it reduces the intracellular concentra-
tion of both species and prevents cellular acidification.
Some indirect observations support the view that lactate
transport controls lactate utilization in skeletal muscle. As
such, under many different experimental conditions there is
a considerable inward-directed lactate gradient [130-132],
which suggests that the capacity for lactate transport across
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the membrane is not much higher than the internal utiliza-
tion. This remains to be established.
Lactate transport is not subject to acute regulation in mus-
cle. However, there are several examples indicating that lac-
tate transport is regulated in a long-term manner. Thus, lac-
tate uptake is faster in soleus than in extensor digitorum
longus muscle in rats [133] and, similarly, lactate transport is
greater in sarcolemmal vesicles derived from slow-twitch
fibers than in vesicles from fast-twitch fibres [134]. These
data suggest a higher lactate-proton transport rate in red fi-
bres than in white. Furthermore, situations characterized by
up-regulation of lactate transport in skeletal muscle include
exercise training [135, 136], chronic electrical stimulation
[137] or administration of thyroid hormones [138]. In con-
trast, other conditions such as muscle denervation [139,
140], unweighting in rats [141] or aging [134] down-regulate
lactate transport.
Monocarboxylate transporters
Different membrane transporter proteins catalyze the pro-
ton-linked transport of lactate, pyruvate, branched-chain -
ketoacids derived from leucine, valine and isoleucine, -hy-
droxypyruvate, acetoacetate and acetate, which have been
named monocarboxylate transporters. At present, eight dif-
ferent monocarboxylate transporter isoforms have been
identified in human tissues (MCT1-8, the latter also known as
XPCT). An extensive review of monocarboxylate trans-
porters has recently been written by Halestrap and Price
[142].
The first monocarboxylate transporter identified, MCT1,
was isolated from Chinese-hamster ovary cells [143].
MCT1s from human, rat and mouse have now been cloned
and share about 95% sequence identity with Chinese-ham-
ster MCT1 [144-148]. Human MCT1 shares high identity with
human MCT2, MCT3 and MCT 4 (ranging from 45 to 57%)
and lower identity with the rest of the members so far identi-
fied (25 to 30%) [143, 149].
Hydrophobicity analysis of the monocarboxylate trans-
porters suggests a structure with 12 transmembrane seg-
ments, presumed to be -helical. It seems probable that
there are 12 transmembrane domains with the N- and C-ter-
mini oriented to the cytosol. Furthermore, the MCT family
members show the highest sequence conservation in the
putative transmembrane region. Results obtained in studies
of proteolytic digestion [150] are in keeping with a model of
MCT1 like the one shown in Figure 3. In addition, MCT1 does
not show N-glycosylation [146], which raises the question of
the nature of the mechanisms involved in intracellular traffic.
In this connection, there is a possible association of MCT
proteins and an ancillary protein OX-47, which may be in-
strumental in directing MCTs to the cell surface (see review
142). An association between a 12 transmembrane-span-
ning domain protein transporter and an ancillary protein has
been well substantiated for some amino acid transporters.
Transport characteristics of MCT1 have been extensively
studied in human erythrocytes (which only express MCT1) or
after heterologous expression in Xenopus oocytes [151-
154]. Kinetics studies indicate that MCT1 is a proton/lactate
co-transporter that follows an ordered, sequential mecha-
nism [151, 152]. Transport begins with proton binding to the
transporter, which is followed by binding of lactate anion.
Translocation of lactate and proton across the membrane
occurs next, followed by their sequential release on the other
side of the membrane. MCT1 can transport a wide variety of
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Figure 3. Proposed topology of MCT-1.
The sequence shown is that of Cricetulus longicaudatus (Chinese hamster) MCT-1.
short-chain monocarboxylates, the Km values decreasing
as their chain length increases from two to four carbon
atoms. Monocarboxylates substituted in the C-2 and C-3 po-
sitions are good substrates, with the carbonyl group being
especially favored and C-2 substitution preferred over C-3.
Transport of lactate is stereospecific, but not that of other
substrates such as -hydroxybutyrate or 2-chloropropi-
onate. Monocarboxylates with longer-branched aliphatic or
aromatic side chains also bind to the transporter but are not
quickly released following translocation and may act as po-
tent inhibitors. MCT4 has a lower affinity for lactate (Km high-
er than 20 mM) than MCT1 (Km of 0.5 mM) after heterolo-
gous expression in Xenopus oocytes [155]. No functional
data are available for MCT5, MCT6, MCT 7 or XPCT.
Skeletal muscle expresses MCT1 and MCT4 monocar-
boxylate transporters [143, 155-157]. MCT1 expression cor-
relates with its mitochondrial content. Thus, rat muscles en-
riched in slow oxidative fibers express large amounts of
MCT1, whereas muscles with a high content of fast-twitch
glycolytic fibers contain hardly any [155, 156]. Similarly,
there is a positive correlation between MCT1 expression and
the occurrence of type I fibers in human muscles [158]. In
contrast, MCT4 is present in all rat muscles but less in pre-
dominantly oxidative muscle [156] and MCT4 density is in-
dependent of fiber type in human muscle [158]. Heart ex-
presses high levels of MCT1 both in human and rat [142,
143]; MCT1 is found at the cell surface of cardiomyocytes
and is particularly concentrated in the intercalated discs
[142, 143]. MCT1 is not the only monocarboxylate trans-
porter that is expressed in heart although there is some vari-
ability among species; thus, human but not rat heart ex-
presses MCT4 [143], and Syrian hamster heart expresses
MCT2 [159]. Furthermore, Northern blot data suggest that
both human skeletal muscle and heart express other mono-
carboxylate transporters with as yet unknown functions:
skeletal muscle expresses MCT6 and XPCT and heart ex-
presses MCT5, MCT6, MCT7 and XPCT [149]. In all, data so
far available indicate the expression of different MCT iso-
forms in skeletal and cardiac muscle; further studies will be
required to characterize the specific cellular distribution.
The distribution of MCT1 and MCT4 in different muscle fibers
has led to the suggestion that MCT1 expression in skeletal
muscle may reflect the need to take up lactate for oxidative
purposes, whereas MCT4 may be important for lactate ef-
flux. A lot of research is still required before the function of
these MCT isoforms in muscle can be demonstrated.
In keeping with the observations that lactate uptake is
regulated in muscle, it is becoming clear that the expression
of MCTs is subject to regulation in muscle. Endurance exer-
cise and high-intensity chronic electrical stimulation en-
hance MCT1 expression in rat skeletal muscle [156, 160]
and exercise training also increases MCT1 in rat heart [160].
In humans, exercise training causes MCT1 up-regulation in
muscle [161]. In contrast, muscle denervation reduces the
expression of both MCT1 and MCT4 in muscle [156]. The
mechanisms involved in the regulation of MCT1 and MCT4 in
muscle remain to be determined.
How do fatty acids cross the plasma membrane in
muscle?
Muscle utilizes large amounts of fatty acids: for example, a
large percentage of the energy required to run a marathon
race is derived from muscular oxidation of fatty acids, most
of which come from the bloodstream. The mechanisms by
which fatty acids cross the membrane are controversial. On
the one hand, there is evidence from unilamellar protein-free
phospholipid vesicles that fatty acids cross membranes effi-
ciently by simple diffusion [162]. On the other hand, some
researchers have provided evidence for carrier-mediated
uptake [163].
Fatty acid diffusion across membranes may be divided
into several steps: a) desorption of the fatty acids from albu-
min to which they are bound, b) absorption of an unbound
monomeric form to the outer leaflet of the plasma mem-
brane, c) passage of fatty acids across the membrane (flip-
flop), and d) desorption of fatty acids from the cytosolic
leaflet of the plasma membrane. The utilization of unilamellar
protein-free phospholipid vesicles has led to reports that the
rate constant for adsorption of fatty acid monomers or for ad-
sorption of fatty acids bound to albumin (at high fatty acid/al-
bumin ratio) to phospholipid bilayer vesicles is extremely
high [164-166]. A more controversial aspect is the trans-
membrane movement of fatty acids or flip-flop across the
membrane. Many studies use the pH-sensitive fluorophore
pyranin to measure rates of flip-flop of fatty acids into phos-
pholipid vesicles; some studies have shown that rates of flip-
flop are high enough to account for fatty acid uptake into
cells (rate constant for flip-flop > 10 s-1) [166, 167]. In con-
trast, other studies in which flip-flop of long chain anthroy-
loxy fatty acids has been measured show that the rate is low
(rate constant < 0.003 s-1) [168]. The rate of fatty acid des-
orption from membranes is slower than the rates of adsorp-
tion and depends on fatty acid length and unsaturation
[162]. However, there is controversy as to whether the rates
of fatty acid desorption are lower or higher than flip-flop
[162, 168]. Thus, these studies performed in model systems
suggest that proteins are not essential for the movement of
fatty acids across membranes, although there is discussion
on the rates and rate-limiting steps.
There is also growing evidence suggesting a carrier-me-
diated uptake of fatty acids into cells which is based on: a)
the saturation kinetics of fatty acid uptake [169, 170], which
in rat cardiomyocytes accounts for 80% of palmitate uptake
[169], b) the alteration of fatty acid uptake by covalent modi-
fication of proteins [171, 172], and c) the identification of
several proteins which enhance fatty acid uptake [163]. In
this regard, several membrane-associated proteins have
been identified and are expressed in cardiac and skeletal
muscles, namely, a plasma membrane fatty acid-binding
protein (FABPpm), a fatty acid translocase (FAT) and a fatty
acid transport protein (FATP).
The plasmalemmal FABP, or FABPpm, is a peripheral
membrane protein which is identical to the mitochondrial
isoform of aspartate aminotransferase [173, 174]. The cellu-
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lar mechanisms by which the mitochondrial isoform of as-
partate aminotransferase reaches the inner side of the plas-
ma membrane and the domain/s that permit binding to the
plasma membrane are not understood. There are several in-
dications that FABPpm participates in the uptake of fatty
acids by cells. Thus, antibodies directed against the
FABPpm diminished oleate uptake in isolated rat cardiomy-
ocytes [175] and in 3T3-L1 adipocytes [176]. They also re-
duced palmitate uptake in preparations of giant sarcolem-
mal vesicles isolated from heart or skeletal muscle [177].
Inhibition with antibodies suggests that FABPpm may ac-
count for up to 50% of fatty acid uptake. Furthermore, 3T3 fi-
broblasts transfected with FABPpm/aspartate aminotrans-
ferase show enhanced saturable oleate uptake in parallel to
an increase in FABPpm bound to the plasma membrane
[178]. The mechanisms by which FABPpm mediates fatty
acid uptake remain unknown. In this regard, the precise role
of FABPpm in fatty acid transport across phospholipid vesi-
cles must be determined.
Recent reports indicate that FABPpm expression is regu-
lated in muscles. Thus, the expression of FABPpm protein
and mRNA is very high in heart, intermediate in red skeletal
muscle and lower in white muscle, which parallels the ca-
pacity of fat oxidation [177, 179, 180]. Furthermore, en-
durance training, which enhances the capacity for fatty acid
oxidation in muscle, also increases FABPpm [181].
Fatty acid translocase (FAT) is an integral membrane pro-
tein which is considered the rat homologue of human CD36
[182] and which binds fatty acids. FAT has two predicted
transmembrane domains and is oriented so that it has two
short intracellular segments (Figure 4). The remaining part of
FAT is extracellular, containing 10 potential N-linked glyco-
sylation sites, which may explain why the molecular mass of
the isolated protein (88 kDa) is much greater than the mass
deduced from the cDNA sequence (53 kDa). Studies on the
purified bovine isoform of CD36 indicate that the six central-
ly clustered cysteines are linked by disulfide bonds, result-
ing in 1-3, 2-6 and 4-5 arrangements of the disulfide bridges
[183]. Based on the homology with the fatty acid binding site
of heart-type fatty acid-binding protein (H-FABP), a potential
binding site for fatty acids may lie in its extracellular segment
between residues 127 and 279 [184]. Several observations
support a role of FAT in fatty acid uptake by cells, namely
that the expression of FAT in Ob17PY fibroblasts (which do
not express endogenous FAT) enhances fatty acid uptake
[185] and that transgenic mice showing muscle-specific
over-expression of FAT are characterized by an enhanced
muscle capacity to oxidize fatty acids in response to muscle
contraction and show low plasma concentrations of triglyc-
erides and fatty acids [186]. As for FABPpm, the mechanism
by which FAT contributes to fatty acid uptake and the extent
of the participation of FAT in the rate of fatty acid uptake by
tissues is unknown. However, FAT has a predicted structure
which does not fit with a membrane transporter, so its role
remains enigmatic. Recently, and perhaps this is germane
to this issue, it was reported that the expression of FAT in
cardiac myocytes in culture does not enhance fatty acid up-
take, which suggests that it requires additional protein com-
ponents for its operation as a «fatty acid translocase» [187].
In any case, as mentioned for FABPpm, studies in liposomes
are required in order to analyze the precise role of FAT.
FAT/CD36 gene was recently identified as a causal gene
for insulin resistance in spontaneously hypertensive rats
(SHR), based on quantitative trait loci mapping in the FAT
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Figure 4. Proposed topology of rat fatty acid translocase (FAT)/CD36.
The asterisks indicate the six centrally clustered cysteines that are linked by disulfide bonds in 1-3, 2-6 and 4-5 arrangements.
gene, defective FAT gene expression in adipose tissue and a
deletional mutation in FAT [188]. However, a further study
demonstrated that FAT gene defect was unlikely to be a ma-
jor cause of insulin-resistance phenotype in SHR since no
mutations in FAT were detected in the original SHR rats [189].
FAT is expressed in muscles and is subject to regulation.
During development, mRNA and protein levels are up-regu-
lated in rat heart, which is parallel to an enhancement of its ca-
pacity to utilize fatty acids [190, 191]. Chronic stimulation in-
creases muscle fatty acid uptake by giant muscle vesicles,
and enhances muscle FAT expression [192]. Furthermore, the
expression of FAT protein and mRNA is very high in heart, in-
termediate in red skeletal muscle and lower in white muscle,
which parallels their capacity of fat oxidation [177, 179, 180].
The mouse fatty acid transport protein (FATP) was initially
identified in an expression cloning strategy by its ability to
enhance fatty acid uptake [193]. Mouse FATP (FATP-1) en-
codes an integral membrane protein with six predicted
membrane-spanning regions, and three potential N-linked
glycosylation sites; both the N-and C-terminal ends are ori-
ented to the cytosolic side (Figure 5). The human, rat and
Saccharomyces cerevisiae orthologues of FATP have been
isolated [194-196]. In fact, a total of five members of the fam-
ily have been identified in murine tissues (FATP1 to 5) and,
at least, FATP-1, FATP-2 and FATP-5 enhance fatty acid up-
take when expressed in COS cells [197]. In addition, FATP
shows homology with rat very long-chain fatty acid CoA syn-
thetases [196].
Stable over-expression of FATP confers enhanced ability
to take up fatty acids [193] and facilitates the uptake of satu-
rated and mono-enoic long-chain fatty acids with 14-22 car-
bons suggesting that it has broad specificity with respect to
fatty acid chain length and degree of saturation [193]. The
mechanism by which FATP facilitates fatty acid uptake is un-
known. In this connection, it has been reported that murine
FATP binds ATP [194], and studies with the yeast orthologue
of FATP indicate that it displays very long-chain fatty acid
synthetase activity, which might be essential for normal very
long-chain fatty acid homeostasis [196]. Comparisons of the
sequences of murine, human and yeast orthologues have
identified a conserved motif IYTSGTTGXPK, also found in a
number of proteins that form adenylated intermediates
[194]. Substitution of alanine for serine 250 in this motif from
murine FATP inhibits long-chain fatty acid uptake and ATP
binding [194]. Taking all these data together, it is reasonable
to propose that FATP facilitates fatty acid uptake via mem-
brane-associated fatty acid CoA synthetase activity rather
than by transport catalysis. However, as for FABPpm and
FAT/CD36, it is crucial to analyze the role of FATP in vesicle
models as well as the effect of in vivo ablation of FATP on fat-
ty acid homeostasis.
FATP is expressed in cardiac and skeletal muscles [182].
Data exist which indicate that its expression is regulated in
adipocytes [198, 199] and muscles [200]. Thus, FATP
mRNA levels are down-regulated in heart, skeletal muscle,
adipose tissue, brain and other tissues in response to
lipopolysaccharide (endotoxin) treatment in vivo under con-
ditions in which fatty acid uptake is reduced [200].
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Figure 5. Proposed topology of mouse fatty acid transport protein FATP-1.
Carnitine uptake is essential for muscle
metabolism
L-carnitine (-hydroxy--trimethylaminobutyric acid) is an es-
sential component in the transport of long-chain fatty acids
into mitochondria, where they undergo -oxidation. The en-
zyme carnitine palmitoyl transferase (CPT-1) catalyzes the
conversion of carnitine and long-chain fatty acids to long-
chain acyl carnitine esters, which are then transported to the
mitochondrial matrix. L-carnitine is synthesized endogenous-
ly from the essential amino acid lysine, with terminal methyl
groups donated by S-adenosylmethionine. Methylation of the
lysine side chain occurs when lysine is present in proteins. In
humans the final reaction in the synthesis of carnitine is cat-
alyzed by a cytosolic hydroxylase, which operates mainly in
liver, brain and kidney, and is not present in cardiac or skele-
tal muscles [201, 202]. In addition to endogenous synthesis,
a notable amount of carnitine is provided by the diet, espe-
cially meat and dairy products. As such, the requirements for
carnitine in cardiac and skeletal muscles are met by uptake
from the extracellular milieu and carnitine is normally main-
tained at a steady level in blood at near 50 µmol/l. It is elimi-
nated as free carnitine or acylcarnitine almost exclusively by
the kidneys, where it is filtered and reabsorbed in the proxi-
mal tubule. The concentrations of carnitine in human heart or
muscle are 20-50-fold greater than in serum [201, 202]. Fail-
ure of muscles to obtain sufficient carnitine results in car-
diomyopathy or muscular weakness.
Carnitine uptake has been studied in different tissues and
cells in culture, and kinetic data suggest the operation of
several transporters. Liver and brain show a low-affinity (Km
in the range of 2-10 mM) high-capacity carnitine uptake
[203-205], while fibroblasts and heart cells have a high-affin-
ity (Km of 5-10 µM) low-capacity system [206-209]. In addi-
tion, kidney brush-border membrane vesicles show both
high-affinity and low-affinity components for carnitine uptake
(Km values of 17 µM and 15 mM, respectively) [210]. Char-
acterization of carnitine transport by renal brush-border
vesicles shows Na+-dependency, electrogenicity and inhibi-
tion by structural analogues such as butyrobetaine, L-acetyl-
carnitine, trimethyl-lysine or D-carnitine [210].
Carnitine uptake by muscle cells varies with the differenti-
ation state; thus, human myoblasts in culture are character-
ized by a high-affinity uptake (Km of 5 µM) [206, 211], and
muscle cell differentiation causes the appearance of a low-
affinity component for carnitine uptake (Km of approximately
0.2 mM) [212, 213]. Carnitine uptake by rat skeletal muscle
is characterized by high Km values, suggesting the opera-
tion of a low-affinity carnitine carrier [214, 215].
Whether the low and high carnitine transport components
identified in different tissues or cells are the result of the ex-
pression of different transporters or correspond to differen-
tial activity states of a single transporter is unknown.
A human gene, named OCTN2, and a rat gene, CT1,
which are very similar (85%) and encode carnitine trans-
porters, have recently been isolated [216, 217]. Human
OCTN2 has been mapped to chromosome 5q31.1-32 [216].
OCTN2 and CT1 belong to the family of organic cation trans-
porters that includes OCT1, OCT2, OCT3 and OCTN1;
OCTN2 is an integral membrane protein showing 12 trans-
membrane domains, 3 potential glycosylation sites in the
first extracellular loops and both the N- and the C-terminal
ends oriented intracellularly [218] (Figure 6). OCTN2 is high-
ly expressed in kidney, heart, skeletal muscle and placenta.
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Figure 6. Proposed topology of human carnitine transporter OCTN-2.
Surprisingly enough, CT1 is mainly expressed in kidney, liv-
er, intestine, testis and placenta and is very weakly ex-
pressed in skeletal muscle, and no expression is detected in
heart [218]. Whether this is due to differences between hu-
man and rat tissues or to CT1 and OCTN2 not being ortholo-
gous remains unknown.
Expression studies of OCTN2 in human embryonic
HEK293 cells indicate that it mediates uptake of carnitine
against a concentration gradient with an apparent
Michaelis-Menten constant of 5-15 µmol/l [218, 219]. One
Na+ is co-transported with one carnitine molecule [219].
Many zwitterionic drugs such as cephaloridine and many
cationic drugs such as verapamil and quinidine inhibit
OCTN2 transport activity [219]. In fact, OCTN2 is a Na+-de-
pendent carnitine transporter as well as a carrier for organic
cations which operates in a Na+-independent manner [220].
This is consistent with the fact that organic cation trans-
porters are Na+-independent [221]. The role of Na+ is to en-
hance the affinity of OCTN2 for carnitine [220].
Primary systemic carnitine deficiency is an autosomal re-
cessive disorder characterized by cardiomyopathy, skeletal
myopathy, hypoglycemia and hyperammonemia. Several
studies indicate that this disease is a consequence of a de-
fect in carnitine transport [208]. This has also been reported
in the mouse model, juvenile visceral steatosis (jvs mice)
[222], which results in renal wastage and very low intracellu-
lar levels of carnitine. Recently, it has been found that sys-
temic carnitine deficiency is caused by mutations in the
OCTN2 gene that lead to deficient cellular carnitine uptake
[223-228].
Several observations suggest additional carnitine trans-
porters, apart from OCTN2, in muscle tissues. These argue
that, as OCTN2 is a high-affinity carnitine carrier and muscle
also expresses a low-affinity carrier, and that myopathic car-
nitine deficiency is characterized by normal concentrations
of carnitine in blood and in liver but low concentrations in
muscle, this gives rise to muscle weakness and lipid storage
myopathy [229]. This raises the question of whether the low-
affinity carnitine carrier is a separate entity and suggests
that a defect in this low-affinity carrier may be the cause of
the primary myopathic carnitine deficiency.
Amino acid release and uptake by muscle is
performed by amino acid transporters
Skeletal muscle constitutes a large proportion of body
weight in most mammals, including Humans. As a conse-
quence of its large mass, muscle is the body’s main reser-
voir of amino acids and protein. Under anabolic conditions,
muscle takes up amino acids from the extracellular space, in
a pattern conforming to its protein composition. In contrast,
in catabolic states or when protein synthesis is depressed,
the pattern of amino acid release from muscle does not de-
pend on the muscle’s protein composition. Thus, alanine
and glutamine account for 40-50% of the total amino acids
released by human forearm and by the isolated perfused rat
hindquarter, whereas they comprise at most 15% of muscle
protein [230-233] as a consequence of the de novo synthe-
sis of alanine and glutamine in muscle [233-235]. In contrast
to alanine and glutamine, several amino acids such as
leucine, isoleucine, valine, aspartate and glutamate are re-
leased from skeletal muscle in lower amounts than would be
expected from their content in muscle protein, probably re-
flecting their active catabolism in muscle [230, 233]. Further-
more, skeletal muscle is a main site of branched-chain
amino acid metabolism; muscle takes up branched-chain
amino acids and converts them into the -ketoacid species
which are released into the circulation [123, 124, 233, 236-
239] (see section on monocarboxylate transporters).
Other amino acids such as glycine, cysteine, serine, thre-
onine, methionine, proline, lysine, arginine, histidine, pheny-
lalanine, tyrosine, and tryptophan can be either removed
from the extracellular space by muscle for incorporation into
protein or released upon proteolysis [123].
This complex pattern of amino acid influx and efflux in
muscle is catalyzed by many different amino acid carriers. In
the early 1960s different substrate specificity transport sys-
tems for amino acids were identified in mammalian cells,
which revealed the existence of general properties of mam-
malian amino acid transport such as stereospecificity and
broad ssubstrate specificity. Since these initial studies, the
main functional criteria used to define amino acid trans-
porters are the type of amino acid carried (zwitterionic,
cationic or anionic) and the thermodynamic properties of the
transport (active transport, facilitative diffusion). This func-
tional classification is still used (Table 1), since structural in-
formation on mammalian amino acid transporters is not com-
plete.
Amino acid transport agencies in muscle
Studies performed on isolated perfused rat hindquarter,
on incubated muscle preparation or on muscle cells in cul-
ture have revealed a number of amino acid transport sys-
tems (Table 1). Most neutral amino acids are transported in
muscle via four distinct transport agencies, i.e. systems A,
ASC and Nm which show Na+-dependency and system L,
which is Na+-independent [240-244]. There is also evidence
for the operation in muscle of the transport of the -amino
acid, taurine, by a Na+-dependent carrier [245]. Cationic
amino acids are transported in muscle by the Na+-indepen-
dent system y+ [246] and aspartate and glutamate are taken
up in muscle cells and in perfused hindquarter via Na+-de-
pendent and Na+-independent mechanisms (Table 1) [246,
247]. Because of the limitations imposed in the studies using
skeletal muscle, it is likely that there are more amino acid
agencies in this tissue than the ones identified by kinetic
means.
There is substantial evidence that system A transport ac-
tivity is regulated in skeletal muscle. Thus, both insulin and
exercise stimulate system A activity in muscle acutely [240,
242, 248-253]. The stimulatory effect of insulin has also been
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Isolated Transport Activity
cDNAs in Muscle
Sodium-dependent ZWITTERIONIC AMINO ACIDS
A Serves mainly for small amino acids. highly regulated. Yes
Tolerates an N-methyl group. Sensitive to pH changes. 
Trans-inhibition associated. Widespread.
ASC Excludes N-methylated amino acids. trans-stimulation associated. ASCT1-2 Yes
Widesread.
N For gin, Asn and His. Sensitive to pH changes. SN1 Yes
Restricted to hepatocytes. Variant Nm in muscle.
BETA Transports -Ala, taurine and GABA. Chloride dependent. series GAT-1 to 3 Yes
Variants known. Widespread. BGT-1, TAUT
GLY Transports Gly and sarcosine. Chloride dependent. Bariants known. GLYT1-2
Present in several tissues
IMINO Handies proline, hydroxyprolines and N-methylated glycines. 
Interacts with MeAIB. In intestinal brush-border membranes.
PHE Phe and Met. In brush-border membranes.
Bo Broad specificity for most zwitterionic amino acids, including 
branched aromatic ones. Accepts BCH but not Me AIB.
In brush-border membranes.
Most probably identical to system NBB (renamed B).
Sodium-independent
L Mainly for bulky side chain amino acids. Trans-stimulated. Bicyclic 4F2hc/LAT-1, -2 Yes
amino acids as model substrates. Variants described. Widespread.
Sodium-dependent CATIONIC AMINO ACIDS
Bo,+ Broad specificity for zwitterionic and dibasic amino acids. Bo,+-AT
Accepts BCH but not with MeAIB. In blastocysts, Xenopus oocytes 
and probably also in brush border membranes.
Sodium-independent
b+ Cation preferring. Does not interact with homoserine even in the 
presence of sodium. Variants known.
y+ Handles cationic, and zwitterionic amino acids with sodium. CAT-1 to 4 Yes
Variants known. Sensitive to N-ethyl maleimide. Widespread.
y+L Handles cationic amino acids, and zwitterionic amino acids with 4F2hc/y-+ LAT-1, -2
high affinity only with sodium. Insensitive to N-ethyl maleimide. 
In erythrocytes and placenta.
b0,+ Like Bo,+ but limited by positions of branching. Hot inhibited by BCH. rBAT/bo,+ -AT
In blastocysts, and in brush border membranes.
Sodium-dependent ANIONIC AMINO ACIDS
X-AG Similarly reactive with L-Glu and D- and L-Asp. K+ -dependent. EAAT1 to 5 Yes
Widespread
Sodium-independent
x-C Cystine completes and exchanges with Glu. In heptocytes and xCT Yes
fibrloblasts. Electroneutral.
MeAIB, methylaminoisobutyric acid; BCH, a-aminoendobicyclo-[2,2,1]-heptane-2-carboxylic acid.
Table 1. Amino acid transport systems present in the plasma membrane of mamalian cells
described in human muscle [254]. In addition, amino acid
starvation up-regulates system A activity in muscle by a
mechanism that requires both protein synthesis and intact
microtubular function [255]. The effect of insulin on system A
in muscle is characterized by an enhanced Vmax of trans-
port, is independent of protein synthesis, independent of the
Na+-electrochemical gradient and does not require intact
microtubular function [253, 255, 256], suggesting a possible
direct effect of insulin on the system A transporter. System A
activity in skeletal muscle is also acutely regulated by phos-
pholipase C and by vanadate [257, 258]; the latter com-
pound may activate system A by increasing the intracellular
pH [258]. System A may also be regulated by long-term
mechanisms and, in this regard, it has been reported that
streptozotocin-induced diabetes causes up-regulation of
system A activity in both red and white muscle [259]. The
precise nature of the mechanisms that regulate system A is
unknown since identification of the system A gene has not
been reported.
The activity of system Nm is responsible for the transport
of glutamine and asparagine in a sodium- and pH-depen-
dent manner, with stoichiometry of 1 Na+:1 glutamine [243,
246]. Nm is responsible for both the influx and the efflux of
glutamine in muscle and is subject to regulation. Glutamine
transport in muscle is up-regulated in response to incuba-
tion in a glutamine-free medium [260], i.e. it undergoes
adaptive regulation. Insulin stimulates Nm activity in muscle
by a mechanism that is characterized by enhanced Vmax
and sensitivity to cycloheximide inhibition [261]. Nm trans-
port activity is also subject to rapid regulation after changes
in cell volume. Thus, hypo-osmotic swelling causes stimula-
tion and hyperosmotic shrinkage induces inhibition of Na+-
dependent glutamine uptake in cultured muscle cells, ef-
fects which are blocked by the phosphatidylinositol
3-kinase, wortmannin [262, 263]. The cloning of one N sys-
tem, named SN1, has recently been reported [264], which
may accelerate the identification of the Nm carrier and thus
the molecular analysis of the regulatory mechanisms that
operate in muscle.
Another system that is subject to regulation in muscle is
the transport of the -amino acid taurine. Taurine uptake
shows sodium dependency in muscle and cardiomyocytes,
and fibre type dictates differences in uptake so that taurine
uptake is greater in red muscle than in white [265]. In addi-
tion, chronic electrical stimulation of the extensor digitorum
longus stimulates taurine transport [266]. In keeping with a
role as an organic osmolyte, hypotonicity strongly activates
taurine efflux from muscle cells in culture [267].
The transport of anionic amino acids is also regulated in
muscle. Thus, insulin increases glutamate uptake by human
forearm muscle [268]. There are differences between the
agencies that participate in glutamate transport in the mus-
cle fiber or in cultured muscle cells. Whereas glutamate
transport in the perfused rat hindlimb shows stereospecifici-
ty and sodium independence [246], glutamate is transport-
ed in muscle cells in culture by Na+-dependent (probably X-
AG) and Na+-independent (probably x-C) agencies [247]. The
sodium-dependent component of glutamate transport is up-
regulated by incubation in the presence of glutamine by a
mechanism that is sensitive to inhibitors of both transcription
and protein synthesis [247].
Expression of amino acid transporters in muscle
The primary sequence of most amino acid transport agen-
cies in mammalian cells has been identified. At present,
amino acid transporters are classified in 5 different gene
families shown in Table 2: 1) family of sodium-independent
cationic amino acid transporters, 2) superfamily of sodium-
and chloride-dependent neurotransmitter transporters
which also includes amino acid transporters, 3) superfamily
of sodium-dependent transporters for anionic and zwitteri-
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Expression
in muscle
A) CATIONIC AMINO ACID TRANSPORTERS
CAT-1 Yes
CAT-2 Yes
CAT-2a Yes
CAT-3
CAT-4
B) SODIUM- AND CHLORIDE-DEPENDENT AMINO ACID
TRANSPORTERS
GAT-1
GAT-2
GAT-3
BGT-1 Yes
TAUT Yes
GLYT1
GLYT2
PROT
B0,+-AT
C) SODIUM-DEPENDENT TRANSPORTERS FOR ANIONIC AND
ZWITTERIONIC AMINO ACIDS
EAAT1 (rat GLAST) Yes
EAAT2 (rat GLT-1)
EAAT3 (rabbit EAAC1) Yes
EAAT4
EAAT5 Yes
ASCT1 Yes
ASCT2 Yes
D) HETEROMULTIMERIC AMINO ACID TRANSPORTERS
Heavy subunit Light subunit
4F2hc Yes
LAT-1
LAT-2 Yes
y+LAT-1
y+LAT-2
xCT
rBAT
b0,+AT
E) SODIUM- AND PROTON-DEPENDENT VESICULAR NEURO-
TRANSMITTER TRANSPORTERS
SN1 
Table 2. Families of amino acid transporters
onic amino acids, 4) family of heteromultimeric amino acid
transporters, with two distinct subunits (Table 2), and 5) the
recently identified SN1 transporter which belongs to the fam-
ily of sodium- and proton-dependent vesicular neurotrans-
mitter transporters, and which is not expressed in muscle
[264]. For a thorough discussion of amino acid transporter
families identified up to 1998, see reference 15.
Most of the work performed up to now in this field has in-
volved molecular identification of the transporters, functional
studies after over-expression in cells, and a few studies on
structure/function relationships and topological properties.
Almost nothing is known about the specific function of these
transporters in muscle. In fact, since the reported informa-
tion is basically limited to the expression of mRNA for trans-
porters in muscle, in many instances we do not even know
whether the transporter is expressed in the muscle fibre or in
cardiac myocytes.
Family of sodium-independent cationic amino acids
These carriers catalyze the sodium-independent transport
of cationic amino acids (L-arginine, L-lysine or L-ornitine)
with high affinity (Km in the micromolar range), as is the case
of CAT-1 or CAT-2, or with low affinity (Km in the millimolar
range) by CAT-2a [269-271]. CAT transporters comprise the
functionally defined cationic amino acid system y+ [269-
272]. Based on Northern blot assays, cardiac and skeletal
muscles are known to express CAT-1, CAT-2 and CAT-2a
[269].
CAT-2 and CAT-2a are isoforms derived from mutually ex-
clusive alternative splicing of the primary transcript, which
differ only in a 41- to 42-amino acid segment located in the
intracellular loop between transmembrane domains VIII and
IX of the 14 transmembrane model (Figure 7) [271].
Transport of cationic amino acids via CAT-1 is voltage-
dependent: hyperpolarization increases the Vmax and de-
creases the Km for influx, and the reverse for efflux [273].
For CAT-1, CAT-2 and CAT-2a, the transport is electrogenic
(positive charge follows the cationic amino acid flux) and
stereospecific [273-275]. In addition, CAT-1, CAT-2 and
CAT-2a have variable trans-stimulation of arginine uptake,
although trans-stimulation of CAT-2a is minimal [276-278].
Structural information on CAT transporters is scarce and
most available data come from the analysis of mouse CAT-1.
CAT transporters lack a characteristic signal peptide and in
consequence the N-terminus is considered to be cytosolic
[270, 272]. Hydrophobicity profiles predict either 12 or 14
transmembrane-spanning domains, although most data
support the 14 transmembrane domain model [15, 279, 280]
(Figure 7).
The specific role of the different CAT transporters ex-
pressed in muscle, CAT-1, CAT-2 and CAT-2a, is unknown.
However, the kinetics of the different CAT transporters and
the plasma and intracellular concentrations of cationic
amino acids lead to the reasonable assumption that CAT-1
and CAT-2, if indeed they are expressed in muscle cells,
participate in the uptake of cationic amino acids, whereas
the low-affinity transporter CAT-2a might be more active in
the efflux of lysine and arginine. In this regard, it is known
that there is differential regulation of these carriers. Thus,
fasting or stress induced in mice by surgical trauma, situa-
tions characterized by muscle protein catabolism and mus-
cle release of cationic amino acids enhance CAT-2a gene
expression in skeletal muscle in the absence of alterations in
CAT-1 or in CAT-2 [281, 282]. Whether the up-regulation of
CAT-2 gene expression contributes to muscle protein catab-
olism by enhancing the release of cationic amino acids from
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Figure 7. Proposed topology of human CAT-1 transporter.
muscle to the extracellular milieu or, alternatively, whether
CAT-2a contributes to the buffering of protein catabolism by
enhancing the expression of a low-affinity transporter, re-
mains unknown.
Family of sodium- and chloride-dependent amino acid
transporters
Different transporters belonging to this family have been iso-
lated and catalyze the uptake of amino acids such as GABA,
betaine, taurine, glycine or proline (Tables 1 and 2) (for re-
view, see 15). The superfamily also includes transporters for
neurotransmitters such as dopamine, serotonin or norepi-
nephrine as well as the creatine transporter reviewed in sec-
tion 3 [283, 284]. Sodium and chloride dependence have
been reported for all these transporters. Skeletal muscle ex-
presses substantial levels of mRNA corresponding to BGT-1
and TAUT [285, 286]; however, no further information is
available. BGT-1 catalyzes the transport of GABA, betaine
and L-proline as assessed in Xenopus oocytes, COS cells or
9HTEo cells [285, 287, 288]. TAUT transporter takes up tau-
rine and -alanine with high affinity after expression in Xeno-
pus oocytes, COS7 cells or HeLa cells [289-292]. The func-
tion of these two transporters in muscle remains unknown;
however, since taurine and betaine are non-perturbing os-
molytes, they may counteract differences in osmolarity be-
tween muscle cells and the extracellular medium. In this re-
gard, the activity of TAUT and BGT1 transporters is
regulated in MDCK renal cells, RAW 264.7 cells or H4IIE rat
hepatoma cells by tonicity [293-295].
The amino acid transporters in this family show high ho-
mology (at least 40%) in their primary structure, with nearly
150 well-conserved amino acid residues [15]. As general
features, all these transporters lack a signal peptide, show a
good prognosis for 12 transmembrane domains, with the N-
and C-terminus located intracellularly, and one to four puta-
tive N-glycosylation sites between transmembrane domains
3 and 4, as shown for the creatine transporter CRT1
(Figure 1). This prognosis has been validated in different
studies for GAT-1 and GLYT1 [296, 297].
Family of sodium-dependent transporters for anionic and
zwitterionic amino acids
This family comprises five anionic amino acid transporters
(EAAT1 to EAAT5) and two zwitterionic amino acid trans-
porters (ASCT1 and ASCT2) (Table 2) which are sodium-de-
pendent (for review, see 15). For a detailed explanation of
the nomenclature used by researchers, see also reference
15. On the basis of sequence homology, this family can be
subdivided into two subfamilies: the human EAAT isoforms
(the anionic transporters), which show 36-65% amino acid
sequence identity between them, and the human zwitterion-
ic amino acid transporters ASCT1 and ASCT2 which show
57% identity between them. The characteristics of their ex-
pressed transport activity suggests that EAAT1-5 isoforms
are variants of the system X-AG, and that ASCT1 and ASCT2
are variants of the system ASC.
Northern blot analysis indicates that skeletal muscle ex-
presses EAAT1 and EAAT3 [298, 299]; EAAT5 may also be
expressed in muscle, although the bands shown in Northern
blot assays for skeletal muscle and heart were near 2.0 kb
whereas the EAAT5 cloned from retina was 3.1 kb [300]. The
precise distribution of EAATs in muscle tissue is unknown,
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Figure 8. Proposed topology of human anionic amino acid transporter EAAT-1.
although they may participate in the muscle uptake of anion-
ic amino acids. Muscle also expresses ASCT1 and ASCT2,
which may contribute to the ASC transport activity reported
in this tissue [301, 302].
The transporters of this family show potassium depen-
dence in addition to sodium dependence when expressed
in different cell systems, with the possible exception of the
zwitterionic amino acid transporters [300, 303, 304]. Thus,
the glutamate transporters are sodium cotransporters and
potassium countertransporters. ASCT1 and ASCT2 are
probably electroneutral sodium-dependent amino acid ex-
changers that do not interact with potassium. Surprisingly
enough, some of these transporters (EAATs and ASCTs)
function as a substrate (amino acid and sodium)-gated chlo-
ride channel in addition to their amino acid transport mode
of action [300, 303, 305]. However, the molecular basis for
this ligand-gated chloride channel activity remains un-
known.
The main common features of the members of this family
are: a) the absence of a cleavable signal sequence, sug-
gesting a cytosolic localization of the N-terminus, b) the
presence of two canonical sites for N-linked glycosylation on
the extracellular loop between transmembrane domains 3
and 4, and c) the presence of six highly conserved putative
membrane-spanning domains in the N-terminal half of the
proteins (Figure 8). There has been controversy on the topol-
ogy of these transporters, which has been resolved for the
rat EAAT2 (named GLT-1) by using single cysteine mutants
and assaying biotinylation [306]. Data indicate that rat
EAAT2 has eight transmembrane domains; between the
seventh and the eighth membrane-spanning domains, a
structure reminiscent of a pore loop and an outward-facing
hydrophobic linker are positioned [306]. This topology is
presented for the isoform EAAT1, which is expressed in
skeletal muscle, in Figure 8.
Family of heteromultimeric amino acid transporters
Very recently, a new family of amino acid transporters has
been identified. All the members of this family are consist of
light subunits, with structure compatible with a transporter,
which must combine with a heavy subunit, either 4F2hc or
rBAT, in order to be fully active [307-316]. Several members
of this family have been identified and show many different
types of sodium-independent amino acid exchange, which
permit the uptake of zwitterionic, anionic or cationic amino
acids (Table 1). Thus, LAT-1 and LAT-2 are variants of L type
transport activity for neutral amino acids [307, 308, 311-
313], y+-LAT-1 and y+-LAT-2 are variants of the transport
system y+-L for cationic amino acids [309, 310], b0,+-AT
functions as the transport system b0,+ with affinity for both
zwitterionic and cationic amino acids [314, 315], and xCT
represents the transport activity system x-C for anionic amino
acids [316]. It is likely that some additional isoforms will be
found in mammalian tissues. Molecular genetics has re-
vealed that rBAT, b0,+-AT and y+-LAT-1 are crucial in renal
function and mutations in those genes have been identified
in cystinuria and in lysinuric protein intolerance [314, 315,
317-319].
The only isoform so far described in skeletal muscle is
LAT-2 [311]. Since co-expression of LAT-2 and 4F2hc in
Xenopus oocytes induces L-type amino acid transport activ-
ity characterized by broad specificity for small (glycine, ala-
nine, serine, threonine and cysteine) and large zwitterionic
amino acids (leucine, isoleucine, phenylalanine, methionine,
tyrosine, histidine, triptophan, valine, asparagine and gluta-
mine) [311], LAT-2 may contribute to the sodium-indepen-
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Figure 9. Proposed topology of human L-amino acid transporter-2, LAT-2.
dent uptake or release of these amino acids in muscle. Be-
cause of the quantitative importance of alanine and gluta-
mine release by muscle in a variety of physiological condi-
tions, we postulate that LAT-2 may contribute to this function
in muscle. In addition, since LAT-2 works as an exchanger, it
is likely that alanine or glutamine release is concomitant to
the uptake of branched-chain amino acids.
Human LAT-2 shows an amino acid sequence identity of
50, 44 and 45% to human LAT-1, y+-LAT-1 and y+-LAT-2, re-
spectively [311]. Hydrophobicity studies suggest 12 trans-
membrane domains with both the N- and C-terminal seg-
ments located intracellularly (Figure 9). There is only one
putative N-glycosylation site between the putative trans-
membrane segments VIII and IX; however, according to the
predictions, this segment is intracellular and additionally is
not glycosylated in an in vitro microsomal system [308],
which is in keeping with the observations on the rest of the
family. No other experimental data have been produced to
support the topological predictions.
LAT-2 interacts with 4F2hc (4F2 cell surface antigen
heavy chain), an ubiquitous membrane protein. The forma-
tion of this complex (with unknown stoichiometry) permits
the arrival of LAT-2 to the cell surface; expression of a
tagged version of LAT-2 in Xenopus oocytes in the absence
of 4F2hc causes its intracellular accumulation and non-ar-
rival at the cell surface [311]. y+-LAT-1 and 4F2hc are linked
by disulfide bridges with residue cysteine 109 of human
4F2hc [311]. Protein 4F2hc has no membrane leader se-
quence so its N-terminus is located intracellularly and a sin-
gle transmembrane domain is predicted, and biochemical
evidence suggests that 4F2hc is a type-II integral mem-
brane N-glycoprotein [320-322].
Future prospects
A major task in the field of plasma membrane transporters
during the last few years has been the identification of their
gene coding. In fact, there is still a lot of work to be done on
the identification of the molecular biology of membrane
transporters, since several important ones such as amino
acid transporters A or Nm have not yet been identified, and
more carnitine transporters or isoforms for known trans-
porters may be identified in the future. The study of the bio-
logical properties of glucose transporters, identified in the
middle to late eighties, has received much more attention
because of their relationship to insulin action and insulin re-
sistance. However, knowledge of the biology of membrane
transporters other than glucose transporters is extremely
scarce. In consequence, it is high time that the precise func-
tion in cells and thus in muscle metabolism of all the identi-
fied membrane transporters with a large metabolism impact
was understood. This will be accomplished by analysis of
the cell biology of these proteins, by generation of trans-
genic animals where the transporter is over-expressed in a
tissue-dependent manner, and by the in vivo ablation of spe-
cific genes in a tissue-specific or time-dependent way. This
is not an easy task, especially in skeletal muscle, due to the
inherent difficulty of this tissue and the lack of good cell
models; for example, much more is known about glucose
transporters in adipose cells than in skeletal muscle, mostly
for the reasons specified above.
These studies seeking to assess cellular function may
also identify new target molecules for therapy. There is a
need for new drugs to ameliorate insulin resistance in type-2
diabetes mellitus and obesity, to prevent and reverse
cachexia induced by many different conditions, and to re-
verse muscle atrophy caused by immobility or aging. We
now know that the GLUT4 glucose transporter is an appro-
priate target for therapy in insulin-resistant states and con-
siderable efforts are being made to identify molecules that
regulate the presence of this transporter at the cell surface.
Perhaps some transporters reviewed in this article may reg-
ulate the size of the muscle fiber or permit the entry of mole-
cules that are important for the proliferation or the differentia-
tion of muscle cells.
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